Anti-snoring Devices and Snoring Surgery Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Oral Appliances/Mouthpieces, Nasal Devices, Position Control Devices, Chin Straps, Tongue Stabilizing Devices, EPAP Therapy Devices) Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 1.72 Billion
CAGR (2026-2031)	7.74%
Fastest Growing Segment	Chin Straps
Largest Market	North America
Market Size (2031)	USD 2.69 Billion

Market Overview

The Global Anti-snoring Devices and Snoring Surgery Market will grow from USD 1.72 Billion in 2025 to USD 2.69 Billion by 2031 at a 7.74% CAGR. Anti-snoring devices comprise oral appliances, nasal dilators, and continuous positive airway pressure machines designed to maintain airway patency, while snoring surgery involves invasive procedures to correct anatomical obstructions. Market growth is fundamentally supported by the rising global prevalence of obesity and an aging demographic increasingly susceptible to sleep-disordered breathing. According to the National Council on Aging, in 2025, approximately 56 percent of adults aged 65 and older are at high risk of developing obstructive sleep apnea. This significant correlation between age and sleep disorders necessitates reliable therapeutic solutions and drives the persistent demand for both surgical and non-surgical interventions.

However, a substantial challenge hindering market expansion is the issue of patient compliance and comfort associated with device usage. Many users report discomfort or claustrophobia when utilizing continuous positive airway pressure masks or mandibular advancement devices which results in high discontinuation rates. This reluctance to adhere to long-term therapy regiments limits potential revenue realization for manufacturers and remains a critical constraint for the broader adoption of anti-snoring technologies globally.

Key Market Drivers

The Increasing Global Incidence of Obstructive Sleep Apnea (OSA) acts as the primary engine for market expansion, fueled by rising obesity rates and an aging global population. As lifestyle-induced respiratory conditions become more prevalent, the pool of patients requiring clinical intervention grows substantially, necessitating robust diagnostic and therapeutic solutions. This escalating burden is highlighted by recent projections; according to ResMed, August 2025, in the press release 'Obstructive Sleep Apnea Expected to Affect Nearly 77 million U.S. Adults by 2050', it is estimated that OSA will affect nearly 77 million adults in the United States alone by 2050. This surge in disease prevalence directly correlates with heightened commercial activity and financial growth for key industry players. Underscoring this economic scale, according to ResMed, in 2025, the company reported a quarterly revenue of $1.3 billion, driven by sustained demand for sleep health devices and masks.

Simultaneously, a Surge in Demand for Minimally Invasive Surgical Interventions is transforming the treatment landscape, particularly for patients struggling with adherence to traditional non-invasive therapies. Surgical options, such as hypoglossal nerve stimulation, are gaining traction as they offer a permanent solution to anatomical obstructions without the discomfort associated with continuous positive airway pressure machines. Technological innovations are further accelerating the adoption of these procedures by improving patient outcomes and reducing surgical complexity. For instance, according to Inspire Medical Systems, November 2025, in the 'Third Quarter 2025 Financial Results', over 75 percent of clinical centers were ready to transition to the newly developed Inspire V system. This high rate of adoption signifies a critical shift towards advanced, minimally invasive modalities as a preferred standard of care for managing severe sleep disorders.

Download Free Sample Report

Key Market Challenges

Patient compliance remains a formidable barrier to revenue growth within the anti-snoring and sleep surgery sector. While the prevalence of sleep disorders warrants widespread device adoption, the intrusive nature of standard treatments, particularly continuous positive airway pressure masks and mandibular advancement devices, creates significant friction. Users frequently report physical intolerance, claustrophobia, and sleep disruption caused by the equipment itself, leading to high abandonment rates shortly after diagnosis. This rejection of prescribed therapy directly undermines the recurring revenue models essential for manufacturers of consumable components and long-term therapeutic hardware.

The scale of this non-adherence significantly contracts the realizable total addressable market. According to the National Sleep Foundation, in 2025, nearly 31 percent of adults diagnosed with sleep apnea were not currently receiving treatment. This data indicates that a vast segment of the diagnosed population effectively exits the market due to intolerance or unwillingness to maintain therapy. Consequently, despite rising diagnosis rates, the industry struggles to convert patient awareness into sustained product usage, thereby stalling potential financial expansion and limiting the overall penetration of anti-snoring technologies.

Key Market Trends

The Emergence of Daytime Neuromuscular Stimulation Therapies represents a paradigm shift from traditional nocturnal interventions to active daytime muscle strengthening. Unlike continuous positive airway pressure machines or oral appliances that must be worn during sleep, these therapies utilize neuromuscular electrical stimulation to improve the endurance of upper airway muscles while the patient is awake. This approach directly addresses the root cause of airway collapse without the physical encumbrance of nighttime hardware, significantly enhancing patient adherence. According to Signifier Medical Technologies, February 2025, in the press release 'Signifier Medical Technologies Secures European Union Medical Device Regulation (EU MDR) Certification for eXciteOSA', clinical data demonstrates that this daytime therapy achieves adherence rates exceeding 80 percent, validating its potential to overcome the chronic non-compliance issues plaguing standard sleep apnea treatments.

Simultaneously, the Widespread Adoption of 3D-Printed Custom Mandibular Devices is revolutionizing oral appliance therapy through precision engineering and enhanced biocompatibility. Manufacturers are leveraging medical-grade 3D printing to create highly personalized splints that offer superior structural integrity and comfort compared to traditional thermoformed devices. These advanced appliances are designed to minimize intraoral bulk, thereby reducing the likelihood of jaw discomfort and facilitating natural tongue positioning. Highlighting this technological progression, according to ProSomnus Sleep Technologies, June 2025, in the press release 'ProSomnus Introduces EVO Guided for the Treatment of Obstructive Sleep Apnea', the newly launched bioengineered device provides up to 14 times more tongue space than predicate devices, a critical feature that improves airway patency and patient comfort during long-term use.

Segmental Insights

The Chin Straps segment is anticipated to witness the most rapid growth within the Global Anti-snoring Devices and Snoring Surgery Market. This trajectory is chiefly attributed to the high patient compliance associated with these non-invasive and cost-effective alternatives to complex surgical procedures or bulky machinery. Additionally, the increasing availability of these products through retail channels significantly enhances consumer accessibility. The supportive regulatory environment, where agencies like the U.S. Food and Drug Administration enforce safety standards for such medical devices, fosters consumer trust and encourages adoption among individuals seeking simple, non-surgical interventions for snoring management.

Regional Insights

North America leads the Global Anti-snoring Devices and Snoring Surgery Market primarily due to the rising prevalence of sleep-related breathing disorders across the United States and Canada. This regional dominance is supported by a robust healthcare infrastructure and high patient awareness regarding obstructive sleep apnea. Furthermore, market expansion is driven by favorable reimbursement policies and frequent product clearances from the U.S. Food and Drug Administration. The concentration of key industry manufacturers within the region ensures consistent availability of medical devices and surgical solutions, fostering steady market development.

Recent Developments

• In August 2025, a company focused on neurostimulation solutions for sleep-disordered breathing announced that the U.S. Food and Drug Administration approved its bilateral hypoglossal nerve stimulation system. This implantable, leadless, and battery-free device was indicated for adult patients with moderate to severe obstructive sleep apnea who had not achieved success with positive airway pressure treatments. The approval was based on positive results from a pivotal clinical study, which showed significant improvements in sleep apnea severity markers. This regulatory success positioned the company to introduce its innovative, minimally invasive therapy to the United States market.
• In November 2024, a medical technology company known for its daytime sleep apnea therapy entered into a strategic distribution partnership with a leading home respiratory equipment provider in the United States. This collaboration was established to expand patient and provider access to the company's FDA-cleared neuromuscular electrical stimulation device, which is designed to treat primary snoring and mild obstructive sleep apnea. By leveraging the partner's extensive network of payers and healthcare professionals, the alliance aimed to facilitate broader adoption of this non-invasive, daytime treatment option for patients seeking alternatives to conventional nighttime therapies.
• In September 2024, a medical device company specializing in breathing disorders received FDA 510(k) clearance for its proprietary oral appliance to treat moderate to severe obstructive sleep apnea and snoring in children aged six to seventeen. This regulatory decision marked the first time an oral medical device was cleared for treating these conditions in a pediatric population. The clearance was supported by data from a prospective clinical trial, which demonstrated that the device significantly reduced snoring and improved airway volume in young patients. This milestone allowed the company to address a critical unmet need in pediatric sleep medicine.
• In August 2024, a medical technology company focused on obstructive sleep apnea solutions announced the FDA approval of its next-generation neurostimulation therapy system. This newly approved system features an updated neurostimulator, a Bluetooth-enabled patient remote, and a physician programmer, representing a significant technological advancement in the company's product portfolio. Following this regulatory milestone, the company revealed plans to initiate a limited commercial launch in late 2024 before expanding to a full release. This development aimed to enhance the treatment experience for patients with moderate to severe sleep apnea who are unable to tolerate continuous positive airway pressure therapies.

Key Market Players

• Apnea Sciences Corp.
• SomnoMed Ltd.
• Airway Management, Inc.
• ResMed Inc.
• Fisher & Paykel Healthcare Corp. Ltd.
• Koninklijke Philips NV
• Sleep Well Enjoy Life, Ltd.
• Tomed Dr. Toussaint GmbH
• MEDiTAS Ltd.
• Sleeping Well, LLC

By Type	By Region
Oral Appliances/Mouthpieces Nasal Devices Position Control Devices Chin Straps Tongue Stabilizing Devices EPAP Therapy Devices	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Anti-snoring Devices and Snoring Surgery Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Anti-snoring Devices and Snoring Surgery Market, By Type:

• Oral Appliances/Mouthpieces
• Nasal Devices
• Position Control Devices
• Chin Straps
• Tongue Stabilizing Devices
• EPAP Therapy Devices

• Anti-snoring Devices and Snoring Surgery Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE